The Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026 requires federal agencies to include reasonable pricing clauses in all research grants and contracts involving biomedical products. Under this provision, U.S. residents cannot be charged more than the median price found in Canada and six other high-income OECD countries for any drug, device, or therapy developed with federal support. The Secretary of Health and Human Services is authorized to establish additional regulations, such as mechanisms to lower prices when revenues exceed targets or costs per health benefit are too high, while retaining the ability to waive these obligations if doing so serves the public interest. To ensure accountability, manufacturers must report clinical trial costs, government subsidies, and annual revenues by county, with all data made publicly available.
The Veterans Medicare Premium Transparency Act requires Medicare to clearly explain how a veteran's enrollment in the Department of Veterans Affairs patient enrollment system affects their monthly insurance premiums. Under this bill, annual notices sent to Medicare beneficiaries will explicitly state that time spent in the VA system counts toward premium calculations and qualifies as valid prescription drug coverage. Additionally, the Secretary of Health and Human Services must post this explanation on the Medicare website and submit a report to Congress within 180 days detailing the updates and estimating how many veterans were previously paying higher premiums due to this lack of clarity.
This resolution expresses support for designating the first week of August as National Community Health Center Week to honor the contributions of these facilities. It encourages all Americans to visit their local health centers during this time to celebrate the partnership between these organizations and the communities they serve. The bill highlights how community health centers provide affordable, comprehensive care to millions of people, particularly in rural and underserved areas, while integrating services like dental care, behavioral health, and pharmacy support. By recognizing these centers, the resolution aims to raise awareness of their role in improving public health outcomes and supporting local economies.
This bill modifies the Public Health Service Act to simplify the process for reviewing biosimilar drugs, which are generic versions of existing biologic medicines. By removing a specific requirement and renumbering a related clause, the legislation aims to reduce regulatory hurdles for manufacturers seeking approval for these products. The change directly impacts pharmaceutical companies and the FDA, potentially allowing for a more efficient evaluation of biosimilars without altering the fundamental safety standards.
The SECURE 340B Act strengthens oversight of the drug discount program for safety-net health care providers by establishing clearer definitions for patients and prescribing providers, requiring detailed record-keeping to prove a legitimate patient relationship. The bill introduces strict rules for contract pharmacies, mandating that manufacturers cannot restrict discounts based on their use and requiring full transparency on where these drugs are dispensed. It also expands eligibility for child sites of covered entities while imposing a new community need standard based on geographic vulnerability scores to prevent abuse. To improve program integrity, the legislation creates a centralized data clearinghouse to track claims and prevent duplicate discounts, while simultaneously prohibiting discriminatory practices by insurance companies and pharmacy benefit managers against covered entities. Finally, the Act authorizes new user fees and additional funding for the Health Resources and Services Administration to support expanded audits and enforcement activities.
The CHECK Act of 2026 requires healthcare intermediaries, such as pharmacy benefit managers and third-party administrators, to provide group health plans with quarterly, detailed reports on their pricing formulas, rebates, and fees without charge. This legislation also mandates that these providers supply specific data on alternative payment models and prohibits contract clauses that delay or restrict access to this financial information. Additionally, the bill expands transparency for patients by requiring health plans to send itemized explanations of benefits within 45 days of a payment request and obligating healthcare providers to issue itemized bills that include plain language descriptions, billing codes, and charity care information. These new reporting and billing requirements are designed to help plans verify costs and enable patients to better understand their medical expenses. Non-compliance with these disclosure rules could result in civil penalties of up to $100,000 per day for service providers and up to $10,000 per instance for healthcare facilities.
The Modernizing Opioid Treatment Access Act 2.0 of 2026 allows specific addiction medicine specialists to prescribe methadone for opioid use disorder to be dispensed directly through pharmacies, rather than requiring patients to attend traditional treatment clinics. This change permits these qualified doctors to use telemedicine for patient care and requires that the methadone be in a liquid or dispersible tablet form. While the bill maintains existing clinic-based treatment options, it streamlines access by removing the need for pharmacies to obtain separate registrations to dispense the medication. The law also mandates that patients sign informed consent forms explaining how privacy rules differ between clinic and pharmacy settings, and it requires the Drug Enforcement Administration to report on the program's progress to Congress every year.
This bill requires hospitals, laboratories, imaging centers, and ambulatory surgical centers to publicly post detailed price lists for their services, including standard charges, negotiated rates, and discounted cash prices, starting in 2027. It also mandates that private health insurance plans provide consumers with cost-sharing estimates and publish quarterly data on payment rates to doctors and pharmacies beginning in 2029. Additionally, the legislation requires Medicare Advantage and prescription drug plan sponsors to report ownership details for providers and pharmacies they control, while establishing civil penalties for entities that fail to comply with these transparency rules.
The Preserving Patient Access Act requires health insurance plans to grant special enrollment periods when they remove a doctor from their network or stop covering a specific prescription drug that a patient has used recently. Under this bill, Medicare Advantage and individual market plans must allow individuals to join or switch plans within the same year if their current provider becomes out-of-network after a visit within the last two years or if a covered medication is dropped from the formulary within the last six months. These protections apply to both Medicare Advantage plans and private individual market plans, ensuring that patients can maintain access to their preferred doctors and medications without waiting for the annual open enrollment window. The changes are scheduled to take effect for plan years beginning on or after January 1, 2027.
The Modernizing Opioid Treatment Access Act 2.0 of 2026 allows licensed addiction medicine specialists to prescribe methadone for opioid use disorder to be dispensed directly through pharmacies, rather than requiring patients to visit traditional treatment clinics. Under this bill, these practitioners must use electronic prescribing and can only dispense liquid or dispersible tablet formulations, while pharmacies do not need separate registration to handle these prescriptions. The law also permits telemedicine for maintenance or detoxification treatment and requires doctors to obtain informed consent from patients regarding how privacy protections differ between clinic and pharmacy settings. Additionally, the Attorney General can revoke a doctor's registration if a state requests it, and the Drug Enforcement Administration must report annually on the number of registered providers and pharmacies involved in the program.
